Literature DB >> 22562147

Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

S Michael Gharacholou1, Brenda J Larson, Christian C Zuver, Ryan J Wubben, Giorgio Gimelli, Amish N Raval.   

Abstract

Strong evidence exists in favor of rapid transfer of a patient suffering an ST-elevation myocardial infarction (STEMI) to the nearest hospital with primary percutaneous coronary intervention (PCI) capability, assuming the time from first medical contact to balloon inflation can be achieved in less than 90 min. In many areas, PCI hospitals have successfully collaborated with regional non-PCI hospitals to provide primary PCI for STEMI; however, significant variations exist in how these programs are executed. For example, the pre PCI hospital administration of antithrombotic agents by emergency medical personnel can include aspirin, clopidogrel, unfractionated heparin, low molecular weight heparin, partial or full dose fibrinolytics or combinations thereof. There is little consensus on the optimal cocktail, dose and route of administration. Standardizing the pre PCI antithrombotic regimen across hospital systems may be one approach to improve timely administration of these therapies, and potentially improve STEMI outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562147     DOI: 10.1007/s11239-012-0744-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  65 in total

1.  Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol.

Authors:  Henry H Ting; Charanjit S Rihal; Bernard J Gersh; Luis H Haro; Christine M Bjerke; Ryan J Lennon; Choon-Chern Lim; John F Bresnahan; Allan S Jaffe; David R Holmes; Malcolm R Bell
Journal:  Circulation       Date:  2007-08-01       Impact factor: 29.690

2.  Rapid triage and transport of patients with ST-elevation myocardial infarction for percutaneous coronary intervention in a rural health system.

Authors:  James C Blankenship; Thomas A Haldis; G Craig Wood; Kimberly A Skelding; Thomas Scott; Francis J Menapace
Journal:  Am J Cardiol       Date:  2007-07-02       Impact factor: 2.778

3.  The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.

Authors:  Benjamin M Scirica; Marc S Sabatine; David A Morrow; C Michael Gibson; Sabina A Murphy; Stephen D Wiviott; Robert P Giugliano; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2006-06-12       Impact factor: 24.094

Review 4.  Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Authors:  David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel E Salazar
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

Review 5.  Aspirin as an antiplatelet drug.

Authors:  C Patrono
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

6.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

7.  Interaction between cigarette smoking and clinical benefit of clopidogrel.

Authors:  Nihar R Desai; Jessica L Mega; Songtao Jiang; Christopher P Cannon; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

8.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

9.  2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.

Authors:  Charles V Pollack; Elliott M Antman; Judd E Hollander
Journal:  Ann Emerg Med       Date:  2008-06-02       Impact factor: 5.721

10.  Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.

Authors:  Jeffrey S Berger; Amanda Stebbins; Christopher B Granger; Eric M Ohman; Paul W Armstrong; Frans Van de Werf; Harvey D White; R John Simes; Robert A Harrington; Robert M Califf; Eric D Peterson
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

View more
  1 in total

1.  Outcomes of Physician-Staffed Versus Non-Physician-Staffed Helicopter Transport for ST-Elevation Myocardial Infarction.

Authors:  Sverrir I Gunnarsson; Joseph Mitchell; Mary S Busch; Brenda Larson; S Michael Gharacholou; Zhanhai Li; Amish N Raval
Journal:  J Am Heart Assoc       Date:  2017-02-02       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.